Size, Share & Industry Analysis, By Type (Blood Biomarkers, Urine Biomarkers, Serum Biomarkers), By Application (Hospitals, Clinics, Cancer Institutes, Research Laboratories), By End User (Diagnostic Laboratories, Academic & Research Institutions, Pharmaceutical Companies, Biotechnology Firms), By Biomarker Function (Diagnostic Biomarkers, Prognostic Biomarkers, Predictive Biomarkers), and Global Forecast, 2026-2034
Explore the report section by section.
The global prostate Cancer Biomarker Market reached USD 1.600 billion in 2025 and is estimated at USD 1.756 billion in 2026. Revenue is forecast to reach USD 3.704 billion by 2034, equivalent to a 9.8% CAGR over 2026–2034.
Prostate cancer biomarkers include serum proteins, urine RNA signatures, tissue-based genomic classifiers and other assays that inform detection, biopsy decisions, prognosis or treatment selection. Prostate-specific antigen remains the broadest-volume blood test, while Decipher, Prolaris, ExoDx and Confirm mdx address narrower clinical questions. The revenue boundary includes assays and laboratory testing attributable to prostate cancer, not the value of imaging, biopsy procedures or anticancer medicines.
The International Agency for Research on Cancer reported more than 1.5 million prostate cancer diagnoses globally in 2022, with pronounced differences in disease burden between countries. PSA elevation can arise from benign enlargement or inflammation, so abnormal results do not independently establish cancer. Additional molecular tests are used in selected pathways to help decide whether biopsy, surveillance or more intensive therapy is appropriate.
Veracyte reported USD 310.7 million in Decipher revenue for 2025, up 27% year on year, while mdxhealth reported USD 107.9 million in companywide revenue. These are different commercial scopes: Veracyte focuses on tissue-based genomic risk classification, and mdxhealth sells several urine and tissue assays. The companies cannot be treated as complete global market totals, but their disclosures substantiate recurring demand for differentiated testing.
During 2025 mdxhealth acquired Exosome Diagnostics from Bio-Techne, consolidating the ExoDx urine assay with Confirm mdx and other tests. In 2026 Noridian updated Medicare molecular-biomarker coding to include ExoDx Prostate. Meanwhile, Veracyte presented clinical evidence on using Decipher to select hormonal or chemotherapy intensification, increasing the relevance of molecular results after initial diagnosis. Clinical utility evidence and Medicare coverage criteria remain important purchasing considerations for U.S. urology and oncology practices.
Source: IARC; National Cancer Institute; Veracyte; mdxhealth.
Revenue includes prostate-cancer-specific biomarker assays, associated reagents and testing services used in screening support, biopsy triage, prognosis and therapy selection; unrelated tumor profiling and therapeutic drug revenue are excluded.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD million/billion |
| By Type | Blood Biomarkers; Urine Biomarkers; Serum Biomarkers |
| By Application | Hospitals; Clinics; Cancer Institutes; Research Laboratories |
| By End User | Diagnostic Laboratories; Academic & Research Institutions; Pharmaceutical Companies; Biotechnology Firms |
| By Biomarker Function | Diagnostic Biomarkers; Prognostic Biomarkers; Predictive Biomarkers |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | United States; United Kingdom; Japan; Brazil; South Africa |
| Key Market Players | F. Hoffmann-La Roche Ltd; Veracyte, Inc.; mdxhealth SA; Myriad Genetics, Inc.; OPKO Health, Inc.; Thermo Fisher Scientific Inc.; Beckman Coulter, Inc.; QIAGEN N.V.; Illumina, Inc.; Agilent Technologies, Inc.; Bio-Rad Laboratories, Inc.; Exact Sciences Corporation |
Blood Biomarkers includes serum and plasma PSA, free PSA, kallikrein panels and circulating molecular analytes; Serum Biomarkers is restricted to serum-specific multiplex signatures outside the conventional blood category, preventing a double count. Urine Biomarkers covers exosomal RNA, PCA3 and related urine-based tests. Tissue genomic classifiers are allocated under the assay technology and function dimensions rather than being added as a fifth revenue stream.
By Application classifies the institution ordering or directing a test; By End User classifies the entity that performs or consumes the laboratory result. The same assay appears once in each independent allocation axis. Diagnostic Biomarkers are used to detect or risk-stratify disease; Prognostic Biomarkers estimate future course; Predictive Biomarkers help select treatment. Research-only sales count only where the reagent is specifically supplied for prostate cancer biomarker work.
IARC counted more than 1.5 million new prostate cancer diagnoses in 2022, and the age profile of patients creates demand for serial assessment before and after diagnosis. Elevated PSA results often require repeat measurement, magnetic resonance imaging or biopsy. Biomarker suppliers benefit when physicians can use a molecular result to make a clearer management decision, but prevalence alone does not establish reimbursement or justify indiscriminate population screening. National screening recommendations differ across health systems and influence the number of men referred for biomarker testing.
The National Cancer Institute explains that PSA can increase with infection or benign prostate enlargement, creating false-positive concerns. Urine RNA tests and kallikrein algorithms seek to identify men at higher risk of clinically significant cancer before biopsy. OPKO states that 4Kscore combines four kallikrein measurements with clinical variables to aid biopsy decisions. Adoption depends on prospective validation, physician familiarity and demonstrated value beyond MRI, rather than a simple increase in the number of available biomarkers.
Veracyte recorded USD 310.7 million of Decipher revenue in 2025 and has reported randomized-trial analyses examining chemotherapy and hormone-therapy decisions. Tissue-derived expression signatures can inform surveillance intensity or adjuvant treatment after surgery. Myriad positions Prolaris for prognostic assessment in selected patients. The revenue opportunity includes repeat institutional ordering and expanded clinical indications, while each new use requires evidence of improved decisions rather than molecular correlation alone. The 2025 NCI SEER specialized database release linking Decipher results with patient outcomes enables additional real-world studies of clinical usefulness across different treatment pathways.
Noridian revised its molecular-biomarker coding article in June 2026, adding ExoDx Prostate assay code 0005U effective in May. Medicare coverage rules distinguish clinical scenarios and qualifying tests; they do not automatically authorize all molecular panels. Commercial laboratories must maintain analytical quality, report turnaround and documentation supporting medical necessity. Billing clarity can support broader physician adoption, but reimbursement rates and payer utilization controls remain constraints on the revenue captured per test. The revised coding article also identifies the ExoDx assay as a urine-based test, which matters when practices choose among blood, urine and tissue pathways.
Bio-Techne agreed in August 2025 to sell Exosome Diagnostics to mdxhealth, which closed the transaction in September. The acquired ExoDx urine test complements mdxhealth tissue-based and liquid-based prostate testing, broadening its ordering relationships. Veracyte separately expanded Decipher evidence and distribution. Consolidation can reduce duplicated commercial infrastructure and support multi-test menus, but it also increases scrutiny of whether each assay improves patient management at its intended clinical decision point. mdxhealth reported USD 107.9 million in full-year 2025 revenue and expects its expanded liquid-testing menu to support higher physician ordering volumes.
Sources: IARC; National Cancer Institute; Veracyte; mdxhealth; Noridian Medicare.
The National Cancer Institute lists PCA3 as a urine RNA test that may help after a negative biopsy and persistent PSA elevation. Its Early Detection Research Network also describes MyProstateScore 2.0 as an 18-transcript urine assay for identifying clinically significant disease. The 2026 Medicare coding revision for ExoDx strengthens the administrative framework for another noninvasive option. These assays are not interchangeable, because intended populations, specimen handling and decision thresholds differ across manufacturers. Clinical performance must be evaluated in biopsy-naive and previously biopsied populations separately because the risk thresholds and management decisions are not identical.
Veracyte reported in May 2026 that ENZAMET trial data linked Decipher scores with benefit from adding chemotherapy in metastatic prostate cancer. A September 2026 analysis of NRG/RTOG 0815 addressed the benefit of adding short-term hormone therapy to radiation for intermediate-risk patients. Such evidence may move molecular testing from prognosis toward treatment prediction. Implementation will still depend on guideline assessment, physician interpretation and coverage of testing in the specific disease stage. These trial findings concern selected patients and should not be interpreted as proof that every genomic classifier predicts response to every systemic prostate cancer treatment.
The European Commission supported PRAISE-U to align prostate screening protocols and collect evidence across multiple member states. In the United Kingdom, the TRANSFORM trial is testing PSA, genetic tests and faster MRI combinations, while routine population PSA screening is not generally offered. A risk-adapted pathway could increase targeted use of secondary biomarkers without repeating the overtreatment associated with broad PSA-only screening. Outcomes from these trials will influence procurement and laboratory referral practices. PRAISE-U operated from April 2023 through September 2026, providing a defined policy and research framework for targeted screening across participating European countries.
Roche markets Elecsys total and free PSA immunoassays for use on cobas analyzers, allowing high-throughput testing within existing laboratory workflows. Specialized genomic classifiers often require centralized sample processing and digital reporting. Hospitals and independent laboratories therefore evaluate both analytical performance and compatibility with clinical information systems. Automated interpretation can improve consistency, but validation of clinical decisions remains separate from analytical reproducibility and instrument throughput. Roche specifies that the total PSA result can also be used to monitor men already diagnosed with prostate cancer, creating demand beyond initial detection.
mdxhealth completed its acquisition of the ExoDx Prostate test in September 2025 and reported strong liquid-based test volume growth during the final quarter. Veracyte reported higher Decipher volumes and a 27% annual increase in related revenue. These changes create broader test menus for urologists, oncologists and radiation specialists. Buyers increasingly compare the strength of clinical evidence, specimen convenience, turnaround time and payer acceptance rather than relying solely on the number of measured biomarkers. The acquired ExoDx laboratory assets also give mdxhealth control of sample processing, an operational consideration distinct from the intellectual property in the urine assay.
The type allocation separates urine biomarkers from conventional blood and specialized serum molecular signatures. Routine PSA and kallikrein assays underpin high-volume testing, whereas urine molecular assays focus on biopsy triage and serum multiplex methods support additional risk stratification. The classifications are mutually exclusive by primary specimen and commercial product purpose.
Blood Biomarkers represented an estimated ~56% of 2025 revenue. PSA, free PSA and 4Kscore are used across established diagnostic pathways, with automated immunoassays available on routine clinical laboratory instruments. PSA testing can recur during post-treatment monitoring, creating repeat laboratory orders over several years. Clinical specificity limitations encourage selected patients to receive MRI or molecular follow-up rather than repeated PSA alone.
Urine Biomarkers include PCA3, ExoDx and MyProstateScore assays. ExoDx assesses exosomal RNA, while MyProstateScore 2.0 evaluates multiple transcripts. These products seek to improve the decision to biopsy men with uncertain clinical risk. Uptake depends on clinical indication, reimbursement and standardized collection procedures rather than specimen convenience alone.
Serum Biomarkers are reserved for serum-specific multiplex signatures not counted in routine PSA and kallikrein tests. Their commercial use is narrower because physicians already have established blood testing and imaging pathways. Developers must show incremental predictive performance, manageable assay costs and reproducible cutoffs before large diagnostic networks adopt additional serum panels.
By 2034, blood testing should retain the largest value pool while urine molecular assays gain use in selected pre-biopsy pathways. Distinguishing specimen-based groups prevents counting a single assay under both Blood Biomarkers and Serum Biomarkers.
Application classifies the clinical setting that initiates the biomarker decision. Hospitals coordinate large diagnostic programs, while outpatient clinics and specialist cancer centers request assays at different stages of the patient pathway. Research laboratories purchase development and validation materials rather than routine reimbursed patient tests.
Hospitals accounted for an estimated ~46% of 2025 revenue. Multidisciplinary teams connect PSA testing, pathology, MRI, surgery and radiation decisions, creating several clinically distinct biomarker orders. Larger centers can negotiate centralized laboratory contracts and monitor test utilization across specialties.
Clinics include urology and primary-care practices that initiate PSA tests and evaluate patients with elevated results. Molecular triage assays can reduce unnecessary referrals for some men, although confirmatory biopsy remains essential when clinical suspicion persists. Physician education and payer eligibility criteria influence how frequently urology clinics order additional molecular tests.
Cancer Institutes use genomic classifiers after tissue diagnosis to evaluate metastatic risk and possible treatment intensification. Veracyte has published Decipher evidence from randomized trial cohorts, increasing interest in molecularly informed oncology decisions. Cancer institute genomic testing depends on specialist interpretation and clinical evidence linked to treatment decisions.
Research Laboratories buy prostate-specific molecular reagents and profiling services for assay discovery, prospective validation and translational studies. Such spending differs from routine patient testing and is limited to in-scope prostate biomarker applications. Research laboratory purchasing depends on grant funding, validation study schedules and multicenter collaboration milestones.
Hospitals should retain the broadest application share, while specialty cancer institutes may increase their use of predictive genomic classifiers as clinical trial evidence becomes more actionable.
End-user allocation follows the organization that performs or consumes testing, rather than the institution initiating the clinical encounter. Independent and hospital laboratories dominate routine processing, with academic groups and biopharma teams buying assay materials for validation and research.
Diagnostic Laboratories perform PSA assays and many molecular tests using standardized equipment and quality systems. Centralized facilities can spread fixed costs over large volumes and maintain proficiency testing. Specialized tests such as Decipher may require shipment to designated laboratories rather than local processing.
Academic & Research Institutions support biomarker discovery and multicenter validation. The NCI SEER specialized database includes Decipher results linked to real-world patient information, expanding opportunities to study test performance and outcomes. Academic research purchases fluctuate with grant cycles and prospective biomarker validation studies.
Pharmaceutical Companies use biomarker information to stratify trial populations and evaluate treatment response. Predictive tests can help identify groups that benefit from therapy intensification, but assay development for a drug program does not equal an approved companion diagnostic.
Biotechnology Firms develop urine RNA, methylation and sequencing platforms for prostate disease. Commercialization depends on clinical utility, analytical validation, intellectual property and partnerships with regulated laboratories. The 2025 ExoDx acquisition illustrates how smaller technologies may be integrated into larger test portfolios.
Independent laboratory providers should maintain the largest share because reimbursed patient testing produces recurring volumes, while academic and industrial research spending fluctuates with clinical programs.
Biomarker function separates tests by the primary medical question answered. Diagnostic tests inform whether significant cancer may be present; prognostic tests estimate disease course after diagnosis; predictive tests support treatment selection. Each order is assigned to its principal intended clinical use.
Diagnostic Biomarkers account for the greatest share because PSA, free PSA and pre-biopsy risk assays are used before definitive diagnosis. Their value comes from improving decisions around MRI and biopsy while avoiding unnecessary invasive procedures in selected patients.
Prognostic Biomarkers include tissue genomic classifiers that estimate recurrence or metastasis risk. Decipher and Prolaris are used in selected disease stages to inform surveillance or treatment intensity. Payer coverage and clinical evidence must support each specific prognostic use of genomic classifiers.
Predictive Biomarkers evaluate likely benefit from particular treatment regimens. Recent Decipher analyses in metastatic and intermediate-risk prostate cancer address chemotherapy or hormone therapy decisions. Commercial uptake depends on prospective clinical utility and incorporation into practice guidelines.
Diagnostic testing will remain the volume foundation, but predictive use could grow faster if randomized trial analyses lead to clear treatment-selection recommendations and covered indications. Veracyte reported predictive analyses from the ENZAMET and NRG/RTOG 0815 trials in 2026; reimbursement of additional indications will depend on clinical and payer review.
North America leads biomarker revenue through specialist laboratory networks and reimbursement, while Europe has substantial screening research and Asia-Pacific carries large patient populations. Latin America and the Middle East & Africa show uneven access to genomic tests, making PSA and pathology infrastructure central to demand.
North America represented an estimated ~43% of 2025 global revenue, supported by broad PSA availability and a mature specialist molecular-testing sector. Veracyte reported USD 310.7 million in 2025 Decipher revenue and mdxhealth reported USD 107.9 million in total company sales, demonstrating different scales of clinical laboratory business. Medicare molecular-biomarker policies specify qualifying clinical contexts and assay codes, so coverage does not extend automatically to every new test. Urology, radiation oncology and pathology referral networks support centralized testing. Canada also has advanced cancer services, but provincial funding and laboratory procurement affect the speed at which specialized assays become available. The region should continue to lead by value as genomic treatment-selection evidence broadens. The NCI also links Decipher test results to SEER research data, enabling real-world studies of disease course and care patterns. Centralized molecular testing supports national reach, but providers must interpret the score alongside clinical risk factors and pathology.
In the United States, Noridian revised the MolDX molecular-biomarker coding article in June 2026 and included the ExoDx Prostate assay code 0005U, effective May 11. Veracyte also reported new Decipher evidence for chemotherapy and hormone-therapy decisions in 2026. Medicare coverage remains tied to medical necessity and defined clinical scenarios, making payer criteria a direct influence on ordering behavior.
Source: Noridian Medicare.
Europe has substantial prostate cancer incidence and established clinical laboratory infrastructure, but screening policies vary between countries. The European Commission funded PRAISE-U to develop risk-based approaches across participating states, reflecting concern about both delayed diagnosis and overtreatment. Germany, France and the Nordic countries have strong pathology and oncology capabilities, while payer assessment can limit access to newer genomic tests. Commercial adoption depends on evidence that biomarkers improve decisions alongside MRI and standard pathology. Hospitals may use PSA and free PSA assays broadly, but tissue genomic testing is more selective. Harmonized risk-stratification protocols could increase targeted test use without requiring population-wide molecular screening. Roche markets total and free PSA assays in France, illustrating the role of automated blood testing within European laboratory networks. Advanced tissue genomics requires separate clinical validation and payer approval before it becomes a routine part of national care.
The United Kingdom does not generally offer routine PSA screening to all men. NHS guidance says patients may request testing after discussion of benefits and harms, and the TRANSFORM study is evaluating combinations of PSA, genetics and rapid MRI. This policy environment creates demand for validated risk-adapted tools while limiting indiscriminate use of expensive molecular panels. NHS specialist referrals remain important when additional prostate biomarker testing is clinically appropriate.
Source: NHS.
Asia-Pacific combines large populations with widely varying access to molecular diagnostics. Japan, South Korea and Australia have mature clinical laboratory networks; India and Southeast Asia have more heterogeneous reimbursement and specialist availability. Regional demand is linked to cancer diagnosis, aging and expansion of hospital pathology services. PSA testing is technically straightforward and can be deployed on existing immunoassay systems, whereas tissue classifiers and urine RNA tests require stronger laboratory standardization and payer support. Private hospitals may introduce genomic tests ahead of public systems. Market growth will depend on local validation, distribution partnerships and evidence that expensive panels change clinical management. The 2022 IARC data also ranked prostate cancer first among male cancers in Japan, reinforcing the clinical need for risk stratification. However, Japan-specific assay uptake cannot be inferred directly from disease incidence or North American company sales.
IARC estimated 104,318 new prostate cancer cases in Japan in 2022, making it the most frequent cancer among Japanese men in that dataset. Japanese clinicians can use PSA testing within established hospital diagnostics, while adoption of molecular prognostic assays requires evidence, domestic regulatory compliance and reimbursement decisions. High disease incidence does not by itself establish that a proprietary foreign assay is locally approved or reimbursed.
Source: IARC Japan factsheet.
Latin American biomarker demand is shaped by uneven oncology access, differences in private insurance and concentration of molecular laboratories in large cities. Conventional PSA testing is more widely available than multigene risk classifiers, and biopsy pathology remains central to confirmation. Brazil and Mexico have major patient populations, but regional networks face cost and sample-shipping constraints. Reimbursement decisions and public-health screening positions can differ from those in North America. Specialized genomic testing may grow in private oncology centers before broader public coverage. Expansion requires locally validated pathways, specimen logistics and demonstrable clinical value in settings where MRI and biopsy capacity are not uniformly available. Brazilian national and state clinical guidance requires clinicians to distinguish PSA elevation from a definitive cancer diagnosis. Public-sector resource allocation therefore emphasizes diagnostic pathways that combine laboratory testing with specialist assessment and access to confirmatory procedures.
Brazil updated its prostate adenocarcinoma diagnostic and therapeutic guidance in January 2025. State health services also promote PSA evaluation for selected men while national guidance cautions against uncritical population screening. These different care pathways affect whether biomarkers are ordered for symptoms, follow-up or risk assessment. Advanced genomic tests remain concentrated in better-resourced clinical networks rather than uniformly available across the public system.
Source: Brazil Ministry of Health.
The Middle East and Africa include high-income health systems investing in precision oncology and countries where access to basic diagnostic services is the larger constraint. PSA testing can be delivered through general laboratories, but advanced urine and tissue molecular assays require specialist ordering, quality systems and reimbursement. Referral delays, pathology workforce shortages and affordability affect test uptake. Gulf countries may purchase advanced assays through tertiary hospitals and international laboratory partnerships. African public programs often prioritize early cancer detection and reliable biopsy follow-up. Sustainable demand for genomic biomarkers will depend on integrating results into treatment decisions and building laboratory networks that can return clinically useful results. The South African government has supported awareness events and PSA testing, but specialist genomic classifier availability remains dependent on tertiary referral networks. Greater sample transport capacity could help connect regional hospitals with molecular reference laboratories.
South Africa marked World Cancer Day in February 2025 with government-supported screening and awareness services that included PSA testing for men. The country has a significant prostate cancer burden and a mixed public-private healthcare system. Molecular prognostic assays are less accessible than conventional blood testing, making specimen transport, clinical interpretation and funding central to any expansion of specialist biomarker services.
Source: South African Government.
Prostate biomarker suppliers compete across different clinical decisions rather than one interchangeable test category. Roche and other immunoassay vendors supply high-volume PSA workflows, while Veracyte, mdxhealth and Myriad market specialized tissue or urine assays. Commercial success for prostate biomarker laboratories depends on physician referrals, payer coding, clinical evidence and the costs of collecting and processing patient specimens. Veracyte reported USD 310.7 million in Decipher revenue during 2025, whereas mdxhealth reported USD 107.9 million of total company revenue across several diagnostic products. Those figures measure different product portfolios and should not be treated as directly comparable market shares.
Roche offers Elecsys total and free PSA assays on cobas immunoassay systems. Large laboratory installed bases favor standardized blood testing, repeat monitoring and predictable turnaround.
Veracyte markets Decipher, a genomic classifier with evidence across prostate cancer risk groups. Myriad offers Prolaris for selected prognostic assessment, with adoption tied to evidence and coverage.
mdxhealth acquired ExoDx in 2025, combining urine-based testing with Select mdx, Confirm mdx and other services. The mdxhealth integrated assay menu supports urology referral networks and centralized specimen processing.
OPKO developed 4Kscore using four kallikrein measurements and clinical variables. Its FDA-authorized test addresses biopsy decisions, a different medical question from post-diagnosis genomic prognosis.
The commercial shift toward predictive genomics creates opportunities for sequencing and laboratory service providers, but evidence for a specific drug decision must be distinguished from analytical test capability. Illumina, Thermo Fisher, QIAGEN, Agilent and Bio-Rad supply platforms or research tools that can support prostate biomarker work; their companywide revenue cannot be counted as prostate-specific sales.
The 2025 ExoDx ownership change also highlights the need to attribute products to their current parent companies. Bio-Techne transferred Exosome Diagnostics to mdxhealth, so a competitor table should not present both businesses as separate owners of the same test. Manufacturers compete through clinical utility, physician education, payer acceptance and laboratory execution.
The National Cancer Institute describes PSA as a screening-related marker with important specificity limitations. The strongest commercial portfolios therefore link their assays to clear decisions about biopsy, surveillance or treatment intensity. Payer policy can differentiate technically similar products by evidence quality and clinical indication.
29 September 2026: Veracyte announced an NRG/RTOG 0815 Phase III analysis indicating that Decipher results can help identify intermediate-risk patients more likely to benefit from adding short-term androgen deprivation to radiation. The result strengthens the predictive evidence base, although use remains subject to clinician interpretation and coverage decisions. Source
25 September 2026: Veracyte announced eight Decipher-focused presentations at ASTRO 2026, covering prognostic and treatment-intensification questions in prostate cancer. The studies extend molecular risk assessment beyond an initial biopsy and may inform how oncology teams select additional therapy. Veracyte said the presentations include national real-world research and clinical trial cohorts, helping clinicians evaluate the test across disease stages. Source
25 June 2026: Noridian posted an updated MolDX billing and coding article for molecular biomarkers used in prostate cancer risk assessment. The revision added ExoDx Prostate code 0005U effective in May, providing a defined administrative route for eligible clinical testing. The revision addresses reimbursement administration rather than a universal recommendation for molecular testing in every patient with an elevated PSA. Source
30 May 2026: Veracyte reported ENZAMET trial findings linking Decipher results with benefit from chemotherapy added to hormonal therapy in metastatic disease. The analysis expands interest in predictive rather than solely prognostic use of prostate tissue genomics. The reported analysis concerned metastatic disease and should not be generalized to men with low-risk localized cancer under active surveillance. Source
15 September 2025: mdxhealth completed its acquisition of Exosome Diagnostics from Bio-Techne, adding the ExoDx Prostate urine assay and associated laboratory assets. The acquisition consolidated a noninvasive test with the company’s existing tissue and liquid biopsy portfolio. The transfer also changed the current corporate owner of the ExoDx assay, an important detail for procurement and competitor mapping. Source
Global prostate biomarker revenue is forecast to increase from USD 1.756 billion in 2026 to USD 3.704 billion in 2034. The endpoint-consistent CAGR is 9.8%, reflecting wider use of molecular triage and genomic risk classification while conventional PSA testing remains the volume base.
| Forecast Variable | 2025–2026 Position | Commercial Effect Through 2034 |
|---|---|---|
| Screening and triage | PSA and risk-adapted secondary testing | Higher selected testing volume without assuming population-wide screening. |
| Treatment selection | Decipher and other genomic classifiers | Additional oncology indications depend on prospective clinical utility. |
| Laboratory access | Centralized testing and immunoassay networks | Automation and shipping can extend reach beyond tertiary centers. |
| Payer policy | Medicare MolDX and national HTA | Coverage criteria affect assay mix and realized revenue. |
By 2034, the strongest growth opportunity is likely to come from tests that change clinical management rather than from biomarkers measured without a defined decision. A urine assay used to avoid a low-value biopsy addresses a different problem from a genomic classifier used after surgery. Laboratories that match clinical indication to validated test performance can support repeat referrals, whereas assays without evidence of utility may struggle to secure reimbursement.
The United States should remain the largest value market because Medicare molecular-biomarker policies and commercial laboratory networks support specialist testing. European programs such as PRAISE-U and the UK TRANSFORM trial could broaden risk-adapted pathways, although evidence on overdiagnosis will remain important. In Asia-Pacific, patient volume and hospital laboratory capacity create demand, but test pricing and national coverage decisions will influence whether advanced panels move beyond private tertiary care.
Manufacturer portfolios are expected to combine established immunoassays with selected molecular tests. Roche supplies high-volume PSA workflows, while Veracyte and mdxhealth report growing specialized testing businesses. Acquisitions such as the 2025 ExoDx transaction may lower commercial costs by integrating specimen logistics and physician relationships. Genomic classifier suppliers will continue to invest in randomized-trial analyses to support treatment decisions at more disease stages.
Revenue growth may differ from procedure growth because centralized laboratory prices, payer contracts and the balance between routine and advanced tests affect realized value. The forecast assumes wider adoption of clinically supported biomarkers but does not presume that every investigational signature becomes a reimbursed diagnostic. Quality control, analytical reproducibility and the availability of specialist interpretation remain necessary conditions for scale.
Coverage spans revenue boundaries, clinical evidence, product technologies, end-use demand and geographical access for prostate Cancer Biomarker Market.
Global prostate cancer biomarker revenue is estimated at USD 1.756 billion in 2026. The estimate covers prostate-specific blood, urine and tissue molecular testing, including diagnostic and prognostic applications. The defined revenue boundary excludes the cost of MRI imaging, biopsy procedures and anticancer medicines.
The market is projected to grow at 9.8% annually from 2026 to 2034, reaching USD 3.704 billion. Growth reflects expanded molecular biopsy triage, genomic treatment decisions and improved laboratory access, subject to coverage and clinical utility.
PSA and free PSA are established blood biomarkers. Other tests include 4Kscore, PCA3, ExoDx, MyProstateScore, Decipher and Prolaris. Each serves a different clinical question, so a patient may not need every test. Physicians select tests based on symptoms, prior biopsy findings and the decision that needs support.
No. PSA can rise because of benign prostate enlargement, infection or inflammation as well as cancer. Clinicians interpret PSA with age, examination, risk factors and, when appropriate, MRI or biopsy. Validated molecular tests may assist biopsy decisions in selected men with uncertain clinical risk.
North America is the largest region, with an estimated 43% of 2025 revenue. U.S. specialist laboratories, Medicare molecular-biomarker policies and broad PSA testing contribute to its position. European and Asian health systems differ in reimbursement criteria and access to specialized genomic assays. U.S. specialty laboratory coverage and genomic assay volumes contribute materially to this regional lead.
ExoDx is a urine exosome-based assay used in selected pre-biopsy risk assessment. Decipher is a tissue genomic classifier used after a cancer diagnosis to assess risk and help inform treatment decisions. The two tests use different specimen types and address different stages of the prostate cancer pathway.
Some tests help estimate the risk of clinically significant cancer and can support shared decisions about biopsy. They do not replace biopsy when clinical suspicion remains high. Test selection should follow the validated population and the clinician’s assessment.
Coverage depends on the assay, indication and local Medicare contractor policies. Noridian updated molecular-biomarker coding for ExoDx in 2026, but a billing code does not mean all patients qualify. Medicare medical necessity requirements still apply to each specific molecular test and patient indication. Prior authorization and assay-specific billing documentation can also affect whether a patient receives the test.
Roche, Veracyte, mdxhealth, Myriad Genetics and OPKO Health have identifiable prostate testing products. Laboratory technology suppliers also participate, but their companywide revenue should not be confused with prostate-specific biomarker sales. Their products cover different specimen types and medical questions, so direct test-price comparisons are limited.
More evidence may support targeted molecular triage and genomic treatment selection. The strongest uptake is expected for tests that improve clinical decisions alongside PSA, MRI and pathology. Payer scrutiny and prospective assay validation will constrain adoption of unproven prostate biomarker panels.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.